Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn

Pediatric Critical Care Medicine

Volumn 10, Issue 1, 2009, Pages 106-112

  Lakshminrusimha, Satyan ^a   Porta, Nicolas F M ^c   Farrow, Kathryn N ^c   Chen, Bernadette ^c   Gugino, Sylvia F ^b   Kumar, Vasanth H ^a   Russell, James A ^a,b   Steinhorn, Robin H ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cyclic AMP; Newborn; Nitric oxide; Phosphodiesterase; Prostacyclin; Pulmonary hypertension

Indexed keywords

CYCLIC AMP; FORSKOLIN; ILOPROST; INDOMETACIN; MILRINONE; NORADRENALIN; PROPRANOLOL; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EWE; FETUS; LAMB; LUNG PARENCHYMA; NEWBORN; NONHUMAN; PERSISTENT PULMONARY HYPERTENSION; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; SHEEP;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOPROSTENOL; FEMALE; HYPERTENSION, PULMONARY; ILOPROST; MALE; MILRINONE; PREGNANCY; PREGNANCY, ANIMAL; PROBABILITY; PULMONARY ARTERY; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SHEEP, DOMESTIC; VASODILATION;

EID: 70349204001     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181936aee     Document Type: Article

References (41)

1. Walsh-Sukys MC, Tyson JE, Wright LL, et al: Persistent pulmonary hypertension of the newborn in the era before nitric oxide: Practice variation and outcomes. Pediatrics 2000; 105(1 Pt 1):14-20
2. Morin FC III: Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res 1989; 25:245-250
3. Zayek M, Cleveland D, Morin FC III: Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide. J Pediatr 1993; 122(5 Pt 1):743-750
4. Roberts JD Jr, Fineman JR, Morin FC III, et al: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:605-610
5. Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336:597-604
6. De Jaegere AP, van den Anker JN: Endotra-cheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. Eur Respir J 1998; 12:932-934
7. Soditt V, Aring C, Groneck P: Improvement of oxygenation induced by aerosolized pros-tacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med 1997; 23:1275-1278
8. Kaapa P, Koivisto M, Ylikorkala O, et al: Prostacyclin in the treatment of neonatal pulmonary hypertension. J Pediatr 1985; 107:951-953
9. Kelly LK, Porta NF, Goodman DM, et al: Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141:830-832
10. Golzand E, Bar-Oz B, Arad I: Intravenous prostacyclin in the treatment of persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide. Isr Med Assoc J 2005; 7:408-409
11. Baker SE, Hockman RH: Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005; 39:1265-1274
12. Concheiro Guisan A, Sousa Rouco C, Suarez Traba B, et al: Inhaled iloprost: A therapeutic alternative for persistent pulmonary hypertension of the newborn. An Pediatr (Barc) 2005; 63:175-176
13. Jourdan KB, Mason NA, Long L, et al: Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1359-L1369
14. Lincoln TM, Fisher-Simpson V: A comparison of the effects of forskolin and nitroprus-side on cyclic nucleotides and relaxation in the rat aorta. Eur J Pharmacol 1984; 101: 17-27
15. Rabe KF, Tenor H, Dent G, et al: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266:L536-L543
16. Dent G, Magnussen H, Rabe KF: Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994; 172:129-146
17. Rashid N, Morin FC III, Swartz DD, et al: Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation. Pediatr Res 2006; 60:624-629
18. Bassler D, Choong K, McNamara P, et al: Neonatal persistent pulmonary hypertension treated with milrinone: Four case reports. Biol Neonate 2005; 89:1-5
19. Danhaive O, Margossian R, Geva T, et al: Pulmonary hypertension and right ventricular dysfunction in growth-restricted, extremely low birth weight neonates. J Perinatol 2005; 25:495-499
20. Khazin V, Kaufman Y, Zabeeda D, et al: Milrinone and nitric oxide: Combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 2004; 18:156-159
21. Degerman E, Belfrage P, Manganiello VC: Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3) J Biol Chem 1997; 272:6823-6826
22. Palmer D, Maurice DH: Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phos-phodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 2000; 58: 247-252
23. Smith CJ, Krall J, Manganiello VC, et al: Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 1993; 190:516-521
24. Rascon A, Lindgren S, Stavenow L, et al: Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim Biophys Acta 1992; 1134:149-156
25. Gao Y, Zhou H, Ibe BO, et al: Prostaglandins E2 and I2 cause greater relaxations in pulmonary veins than in arteries of newborn lambs. J Appl Physiol 1996; 81:2534-2539
26. Gao Y, Tolsa JF, Shen H, et al: Effect of selective phosphodiesterase inhibitors on response of ovine pulmonary arteries to pros-taglandin E2. J Appl Physiol 1998; 84:13-18
27. Shaul PW, Farrar MA, Magness RR: Prostacyclin synthesis and stimulation of cyclic AMP production in ovine fetal vasculature: Heterogeneity in pulmonary and systemic arteries. Dev Pharmacol Ther 1992; 18: 89-99
28. Steinhorn RH, Morin FC III, Gugino SF, et al: Developmental differences in endothelium-dependent responses in isolated ovine pulmonary arteries and veins. Am J Physiol 1993; 264(6 Pt 2):H2162-H2167
29. Steinhorn RH, Russell JA, Morin FC III: Disruption of cGMP production in pulmonary arteries isolated from fetal lambs with pulmonary hypertension. Am J Physiol 1995; 268(4 Pt 2):H1483-H1489
30. Konduri GG, Ou J, Shi Y, et al: Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 2003; 285: H204-H211
31. Shaul PW, Muntz KH, DeBeltz D, et al: Effects of prolonged hypoxia on adenylate cyclase activity and beta-adrenergic receptors in pulmonary and systemic arteries of the rat. Circ Res 1990; 66:1526-1534
32. Wagner RS, Smith CJ, Taylor AM, et al: Phos-phodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 1997; 282:1650-1657
33. Wild LM, Nickerson PA, Morin FC III: Ligating the ductus arteriosus before birth remodels the pulmonary vasculature of the lamb. Pediatr Res 1989; 25:251-257
34. Steinhorn RH, Morin FC III, Gugino SF, et al: Developmental differences in endothelium-dependent responses in isolated ovine pulmonary arteries and veins. Am J Physiol 1993; 264(6 Pt 2):H2162-H2167
35. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254
36. Beers SA, Malloy EA, Wu W, et al: Nitroaryl-hydroxymethylphosphonic acids as inhibitors of CD45. Bioorg Med Chem 1997; 5:2203-2211
37. Harder KW, Owen P, Wong LK, et al: Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides. Biochem J 1994; 298(Pt 2):395-401
38. Paradisis M, Jiang X, McLachlan AJ, et al: Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F204-F209
39. Tuder RM, Cool CD, Geraci MW, et al: Pros-tacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925-1932
40. Shaul PW, Kinane B, Farrar MA, et al: Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. Alterations after prolonged hypoxia in the rat. J Clin Invest 1991; 88:447-455
41. Moreno L, Losada B, Cogolludo A, et al: Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: Activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Pediatr Res 2004; 56:563-570